HOOKIPA Pharma (HOOK) announced that Katia Schlienger, M.D., Ph.D., is stepping down from her position as Chief Medical Officer, CMO, to pursue new opportunities, effective September 30. Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA’s clinical activities ad interim as Senior Clinical Advisor until a CMO search is complete. During this time, Dr. Peters will remain a member of the HOOKIPA Board of Directors. Dr. Peters retired from his role as Chief Research and Development Officer at MorphoSys (MOR) in 2022.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOOK:
- HOOKIPA Announces Executive Leadership Change
- Hookipa Pharma announces grant of inducement awards under Nasdaq listing rule
- HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- HOOKIPA Pharma to participate in upcoming investor conferences in September
- Hookipa Pharma price target lowered to $6.50 from $8 at H.C. Wainwright